This article appears in the the BreastCancerUpdate Journal Vol 5. The article is edited by Mark D Pegram MD
Associate Professor of Medicine David Geffen School of Medicine at UCLA Director Women’s Cancer Program UCLA/Jonsson Comprehensive Cancer Center. Dr. Pegram covers many topics relevant to HER-2 positive breast cancer treatment including:
Early Phase I experience with trastuzumab/cisplatin in metastatic disease
Phase III randomized trial of trastuzumab/paclitaxel with or without carboplatin
Trastuzumab/platinum/taxane regimens
First-line therapy for patients with HER2-positive metastatic disease
BCIRG-006 adjuvant trastuzumab trial
Adjuvant trastuzumab in the nonprotocol setting
Influence of trastuzumab therapy on tumor HER2 status
Trials combining trastuzumab with hormonal therapy
Fulvestrant in clinical practice
Potential synergy between fulvestrant and trastuzumab
Trials combining trastuzumab with biologic agents (i.e. Erlotinib and Bevacizumab)
Treatment options for patients with ER-negative HER2- negative metastatic disease
Transition from hormonal therapy to chemotherapy
Phase III trial comparing capecitabine with or without bevacizumab
ECOG-E-2100: Phase III trial comparing paclitaxel with or without bevacizumab
Use of adjuvant dose-dense chemotherapy schedules
As you know Dr. Dennis Slamon (father of Herceptin/trastuzumab) is based at UCLA. I find the articles written or edited by the doctors at UCLA insightful.
Of course all treatment options should be discussed fully with your doctor.
|